Research programme: anti-VPAC antibody therapeutics - ThromboGenics

Drug Profile

Research programme: anti-VPAC antibody therapeutics - ThromboGenics

Alternative Names: Anti-VPAC1 antibody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Leuven
  • Developer ThromboGenics
  • Class Monoclonal antibodies
  • Mechanism of Action Pituitary-adenylate-cyclase-activating-polypeptide-type I-receptor-antagonists; Vasoactive intestinal polypeptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in Europe (Parenteral)
  • 14 Nov 2007 Thrombogenics has selected an anti-VPAC antibody candidate for the treatment of thrombocytopenia
  • 22 May 2007 Preclinical trials in Thrombocytopenia in Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top